Tower Research Capital LLC TRC Lowers Stock Position in Esperion Therapeutics, Inc. (NASDAQ:ESPR)

Tower Research Capital LLC TRC cut its stake in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) by 85.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,600 shares of the biopharmaceutical company’s stock after selling 55,914 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Esperion Therapeutics were worth $29,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. raised its holdings in Esperion Therapeutics by 120.1% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 413,704 shares of the biopharmaceutical company’s stock valued at $405,000 after acquiring an additional 225,767 shares during the period. GSA Capital Partners LLP lifted its holdings in Esperion Therapeutics by 159.1% in the 3rd quarter. GSA Capital Partners LLP now owns 1,116,655 shares of the biopharmaceutical company’s stock worth $1,094,000 after purchasing an additional 685,733 shares in the last quarter. PSI Advisors LLC boosted its position in shares of Esperion Therapeutics by 161.5% during the fourth quarter. PSI Advisors LLC now owns 17,000 shares of the biopharmaceutical company’s stock worth $51,000 after acquiring an additional 10,500 shares during the last quarter. Simplicity Solutions LLC purchased a new position in Esperion Therapeutics during the third quarter valued at $30,000. Finally, Pinnacle Associates Ltd. increased its holdings in Esperion Therapeutics by 15.7% in the 3rd quarter. Pinnacle Associates Ltd. now owns 289,123 shares of the biopharmaceutical company’s stock valued at $283,000 after acquiring an additional 39,285 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Wall Street Analysts Forecast Growth

ESPR has been the subject of several research reports. HC Wainwright reissued a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a report on Monday, March 25th. Needham & Company LLC restated a “buy” rating and set a $8.00 price target on shares of Esperion Therapeutics in a report on Wednesday, April 10th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat.com, Esperion Therapeutics currently has an average rating of “Hold” and an average target price of $9.33.

Esperion Therapeutics Price Performance

Shares of Esperion Therapeutics stock traded up $0.02 during trading hours on Friday, reaching $2.08. The company’s stock had a trading volume of 5,530,903 shares, compared to its average volume of 5,833,177. Esperion Therapeutics, Inc. has a one year low of $0.70 and a one year high of $3.40. The firm has a 50 day moving average price of $2.34 and a 200-day moving average price of $2.04. The stock has a market cap of $393.95 million, a P/E ratio of -0.98 and a beta of 0.89.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03. The company had revenue of $32.25 million for the quarter, compared to analysts’ expectations of $26.84 million. During the same quarter last year, the company earned ($0.76) earnings per share. As a group, sell-side analysts forecast that Esperion Therapeutics, Inc. will post -0.68 EPS for the current fiscal year.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.